Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells

Immunology

Volumn 109, Issue 2, 2003, Pages 300-307

  Chen, Dongshu ^a   Xia, Jianchuan ^a,b   Tanaka, Yasuhiro ^a   Chen, Hongsong ^a   Koido, Shigeo ^a   Wernet, Oliver ^a   Mukherjee, Pinku ^c   Gendler, Sandra J ^c   Kufe, Donald ^a   Gong, Jianlin ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL FUSION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS BREEDING; DENDRITIC CELL; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIFESPAN; LONG TERMINAL REPEAT; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONSET AGE; POLYOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSGENIC MOUSE; TREATMENT OUTCOME; VIRUS ONCOGENE;

ANIMALS; ANTIBODIES, NEOPLASM; CA-15-3 ANTIGEN; CANCER VACCINES; CELL FUSION; CELL TRANSPLANTATION; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS;

EID: 0037843019     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01656.x     Document Type: Article

References (41)

1. Hellstrom KE, Hellstrom I. Cellular immunity against tumor antigens. Adv Cancer Res 1969; 12:167-223.
2. Rosato FE. Active specific immunotherapy of human solid tumors. Ann N Y Acad Sci 1976; 277:332-8.
3. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183:725-9.
4. Baum M. Immunotherapy in treatment of breast cancer. Proc R Soc Med 1974; 67:294-6.
5. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51:2908-16.
6. Taylor-Papadimitriou J, D'Souza B, Burchell J, Kyprianou N, Berdichevsky F. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. Ann N Y Acad Sci 1993; 698:31-47.
7. Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther 1999; 1:98-103.
8. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3:223-32.
9. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47:5476-82.
10. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43:1072-6.
11. Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998; 76:817-23.
12. Mukherjee P, Ginardi AR, Madsen CS, Sterner CJ, Adriance MC, Tevethia MJ, Gendler SJ. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 2000; 165:3451-60.
13. Morikane K, Tempero R, Sivinski CL, Kitajima S, Gendler SJ, Hollingsworth MA. Influence of organ site and tumor cell type on MUC1-specific tumor immunity. Int Immunol 2001; 13:233-40.
14. Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin Cancer Res 2001; 7:848s-55s.
15. Mukherjee P, Madsen CS, Ginardi AR et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003; 26:47-62.
16. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-96.
17. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68:106-66.
18. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94:459-73.
19. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12:954-61.
20. Cardiff RD, Muller WJ. Transgenic mouse models of mammary tumorigenesis. Cancer Surv 1993; 16:97-113.
21. Maglione JE, Moghanaki D, Young LJ et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001; 61:8298-305.
22. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998; 58:315-21.
23. Ritland SR, Rowse GJ, Chang Y, Gendler SJ. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 1997; 57:3520-5.
24. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci U S A 1988; 85:2320-3.
25. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693-702.
26. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61.
27. Abe M, Kufe D. Structural analysis of the DF3 human breast carcinoma-associated protein. Cancer Res 1989; 49:2834-9.
28. Sekine H, Ohno T, Kufe DW. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol 1985; 135:3610-5.
29. Abe M, Kufe DW. Identification of a family of high molecular weight tumor-associated glycoproteins. J Immunol 1987; 139:257-61.
30. Abe M, Kufe D. Effects of maturational agents on expression and secretion of two partially characterized high molecular weight milk-related glycoproteins in MCF-7 breast carcinoma cells. J Cell Physiol 1986; 126:126-32.
31. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000; 50:7-33.
32. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6:339-53.
33. Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, Kufe DW. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun 1989; 1:261-7.
34. Perey L, Hayes DF, Kufe D. Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res 1992; 52:6365-70.
35. Gong J, Apostolopoulos V, Chen D, Chen H, Koido S, Gendler SJ, McKenzie IF, Kufe D. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000; 101:316-24.
36. Gong J, Chen D, Kashiwaba M et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998; 95:6279-83.
37. Courtneidge SA, Smith AE. Polyoma virus transforming protein associates with the product of the c- src cellular gene. Nature 1983; 303:435-9.
38. Kornbluth S, Sudol M, Hanafusa H. Association of the polyomavirus middle-T antigen with c-yes protein. Nature 1987; 325:171-3.
39. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994; 8:23-32.
40. Webster MA, Hutchinson JN, Rauh MJ et al. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998; 18:2344-59.
41. Dankort DL, Muller WJ. Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene 2000; 19:1038-44.